GPT Healthcare operates a chain of multi-specialty tertiary and quaternary care hospitals under the ILS brand across Eastern and Central India, with six operating units in Kolkata (Salt Lake, Dumdum, Howrah), Agartala, Raipur and a 155-bed hospital under construction in Jamshedpur. Its revenue is generated from advanced procedures such as robotic surgeries, renal and liver transplants, oncology, and cardiac care, with roughly 90% of revenue coming from cash and insurance patients rather than government schemes. The network currently has about 700 beds, and management targets a 1,000-bed footprint by 2027 through Jamshedpur and a seventh hospital. The business quality shows in the ex-Raipur EBITDA margin of 23.06% in FY26, while the overall margin was dragged to 18.84% by the newly commissioned Raipur facility; FY27 guidance points to roughly 21% as that drag fades. This is a niche position in underserved eastern Indian markets, where GPT is often the first corporate entrant, not a commodity hospital scale play.
The persistence of these economics rests on clinical capability and location exclusivity. Agartala is the only corporate tertiary care hospital in Tripura, and Howrah is the first corporate hospital in its micro-market; Salt Lake has completed more than 800 robotic procedures and Dumdum has performed more than 700 renal transplants, giving these units referral stickiness that new entrants cannot quickly replicate. NABH accreditation at Raipur came in 13 months, and the hospital completed its first liver transplant within about a year of commissioning, evidence of a team that can scale clinical protocols. Payer mix is another barrier: 90% of revenue is cash or insurance, indicating pricing power and limited exposure to low-margin government schemes. Management also reports single-digit doctor attrition in Kolkata and around 10% in Agartala and Raipur, supporting continuity in specialty care. However, the moat is not absolute; Raipur is seeing new competitors and the asset-light rental model means GPT does not own the real estate, so long-term economics hinge on sustaining occupancy rather than on land appreciation.
The next 18 to 24 months are defined by the commissioning and ramp-up of two greenfield hospitals. Jamshedpur, a 155-bed facility with capex of about INR70 lakhs per bed, is guided to be commissioned in Q4 FY27 by March 2027 but may slip to Q1 FY28 if approvals delay; it is expected to incur initial losses of INR3-4 crores in FY27 and follow Raipur's ramp curve. Raipur, which exited FY26 with only 12-14% occupancy and an EBITDA loss of INR13.8 crores for the year, is guided to reach roughly 30% occupancy by the end of FY27 and monthly EBITDA breakeven by Q3 FY27, turning fully EBITDA positive in FY28. Mature hospitals Salt Lake and Dumdum are expected to reach 70-73% occupancy in FY27, while Agartala and Howrah move toward 58-60%. By the middle of 2028, the network should have over 1,000 beds, Raipur contributing positive EBITDA, and Jamshedpur in its second year of ramp; revenue growth is guided at 15% for FY27 with ARPOB growth of about 8% from tariff increases and specialty mix. Management expects FY27 EBITDA margin near 21% and EBITDA of INR110-115 crores including other income, up from FY26's 18.84% margin.
Management's track record is mixed on headline numbers but better on operational milestones. On the Feb 2026 call, they guided Raipur to monthly EBITDA breakeven in 6-8 months and a 15% FY27 revenue growth; 9MFY26 revenue growth came in at 12.12% and the 9M EBITDA margin was 18.58%, below the 22-23% band previously discussed. However, Raipur's quarterly loss of INR3 crores in Q1 FY27 was better than the earlier INR4.5 crore per quarter assumption, and occupancy ramps have broadly tracked: Raipur went from 7% to 17% occupancy year-on-year, and Salt Lake improved from 60% to 62%. Management has not cut FY27 guidance; it reaffirmed 15% revenue growth, an 8% ARPOB increase, and roughly 21% EBITDA margin. On capital allocation, the company is using an asset-light model for Raipur and Jamshedpur with third-party long-term rentals, expects to draw about INR25 crores of debt for Jamshedpur in FY27, and targets long-term ROE and ROCE around 25%. The guidance monitor classifies the latest stance as upgraded, but the credibility gap between previously promised 22-23% margins and delivered ~19% requires ongoing verification.
The quantified earnings path to late FY28 is clear: FY27 EBITDA of INR110-115 crores at roughly 21% margin; Raipur moving from loss to breakeven; mature hospitals growing at high single to low double digits; and Jamshedpur adding revenue but initially loss-making. For that to hold, Raipur must sustain its insurance empanelment completion, guided done in Q1 FY27, and reach the 30% occupancy exit without further payer-mix dilution to low-ARPOB schemes, while Jamshedpur must not slip beyond a single quarter. The single most important watchpoint is Jamshedpur's commissioning date and the pace of Raipur's occupancy ramp, because both determine whether the network's fixed-cost base converts into operating leverage. A falsifier would be another year of 12% revenue growth while margins stay below 19%, which would indicate that new hospitals are not scaling and the asset-light model is just adding lease costs. The tension in the data is that management has historically missed headline growth and margin targets while hitting clinical and occupancy milestones; the resolution is operational rather than structural only if Jamshedpur and Raipur reach their stated occupancy thresholds by the end of FY27. If they do, the company exits FY28 with a materially higher margin and a larger, more diversified bed base.
companyname: GPT Healthcare Limited ticker: GPTHEALTH sector: Healthcare - Multispecialty Tertiary Care Hospitals GPT Healthcare Limited is the healthcare arm of the GPT Group, a Kolkata-based conglomerate with over 40 years across infrastructure, manufacturing, and healthcare. The company owns and operates five full-service multispecialty tertiary care hospitals under the ILS Hospitals brand, spread across three states - West Bengal, Tripura, and Chhattisgarh - with a sixth under construction ...
Read the full report →capex, margin expansion, new product segment, geographic expansion
FY27 revenue growth guided at 15% driven by occupancy improvements and specialty mix optimization
Guidance upgradedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for GPT Healthcare Limited and 4,900+ companies.
5-day free pass. No card required.